Galectin Therapeutics (GALT) Free Cash Flow (2010 - 2026)

Galectin Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$3.9 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 49.72% year-over-year to -$3.9 million in Q1 2026; TTM through Mar 2026 was -$20.1 million, a 46.25% increase from a year earlier, with the FY2025 full-year figure at -$23.9 million, up 42.78% from the prior year.
• Free Cash Flow grew to -$3.9 million in Q1 2026 per GALT's latest filing, from -$6.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$3.5 million in Q3 2025 and bottomed at -$12.8 million in Q4 2024.
• The 5-year median for Free Cash Flow is -$7.7 million (2025), against an average of -$7.9 million.
• Across the five-year window, Free Cash Flow sank 170.02% in 2024 and soared 59.19% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$7.2 million in 2022, then surged by 34.56% to -$4.7 million in 2023, then sank by 170.02% to -$12.8 million in 2024, then surged by 52.31% to -$6.1 million in 2025, then soared by 36.62% to -$3.9 million in 2026.
• Per Business Quant, the three latest GALT Free Cash Flow figures stand at -$3.9 million (Q1 2026), -$6.1 million (Q4 2025), and -$3.5 million (Q3 2025).